3588-64-5

Usage

Synthesis Reference(s)

Journal of the American Chemical Society, 71, p. 1856, 1949 DOI: 10.1021/ja01173a095

InChI:InChI=1/C17H13NO4/c19-15-12-8-4-5-9-13(12)16(20)18(15)14(17(21)22)10-11-6-2-1-3-7-11/h1-9,14H,10H2,(H,21,22)

Upstream product

• 85-44-9 phthalic anhydride 
• 150-30-1 Phenylalanine 
• 5452-63-1 benzyl-(2-carboxy-benzoylamino)-malonic acid 
• 22509-74-6 N-ethoxycarbonylphthalimide 
• 1242459-38-6 C₂₃H₂₉NO₄Si₂ 
• 673-06-3 D-(R)-phenylalanine 
• 673-06-3 D-β-Phenyl-α-alanine 
• 63-91-2 L-phenylalanine 
• 63-91-2 L-phenylalanine 

Downstream Products

• 99481-69-3 2-phthalimido-N,3-diphenylpropanamide 
• 76249-23-5 N-(N,N-phthaloyl-DL-phenylalanyl)-glycin-ethyl ester 
• 114863-26-2 benzoic acid-(N,N-phthaloyl-DL-phenylalanine)-anhydride 
• 21662-02-2 N,N'-dicyclohexyl-N-(N,N-phthaloyl-phenylalanyl)-urea 
• 34695-69-7 N,N-phthaloyl-phenylalanyl=>glycyl=>-glycin-ethyl ester 
• 56271-33-1 3-phenyl-2-(phthalimido)propanoyl chloride 
• 65919-40-6 N,N-phthaloyl-DL-phenylalanine thiazol-2-ylamide 
• 5426-73-3 2-amino-N,3-diphenylpropanamide 
• 84708-66-7 9-(N-phthalyl-DL-phenylalanyl)carbazole 
• 87119-92-4 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-phenyl-N-pyrazin-2-yl-propionamide 
• 78211-04-8 2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-N-(2-imino-thiazolo[4,5-b]quinoxalin-3-yl)-3-phenyl-propionamide 
• 78221-01-9 2-(N-Pht-DL-Phe)-aminobenzothiazole 
• 74036-09-2 2-(1-oxo-indan-2-yl)-isoindole-1,3-dione 
• 111319-37-0 (3,4-Dimethoxyphenyl)-(2-phenyl-1-phthalimidoethyl)-keton 

Relevant academic research and scientific papers

Amino acid conjugates of aminothiazole and aminopyridine as potential anticancer agents: Synthesis, molecular docking and in vitro evaluation

Purpose: The development of resistance to available anticancer drugs is increasingly becoming a major challenge and new chemical entities could be unveiled to compensate this therapeutic failure. The current study demonstrated the synthesis of 2-aminothiazole [S3 (a-d) and S5(a-d)] and 2-aminopyridine [S4(a-d) and S6(a-d)] derivatives that can target multiple cellular networks implicated in cancer development. Methods: Biological assays were performed to investigate the antioxidant and anticancer potential of synthesized compounds. Redox imbalance and oxidative stress are hallmarks of cancer, therefore, synthesized compounds were preliminarily screened for their antioxidant activity using DPPH assay, and further five derivatives S3b, S3c, S4c, S5b, and S6c, with significant antioxidant potential, were selected for investigation of in vitro anticancer potential. The cytotoxic activities were evaluated against the parent (A2780) and cisplatin-resistant (A2780CISR) ovarian cancer cell lines. Further, Molecular docking studies of active compounds were performed to determine binding affinities. Results: Results revealed that S3c, S5b, and S6c displayed promising inhibition in cisplatin-resistant cell lines in comparison to parent cells in terms of both resistance factor (RF) and IC50 values. Moreover, S3c proved to be most active compound in both parent and resistant cell lines with IC50 values 15.57 μM and 11.52 μM respectively. Our docking studies demonstrated that compounds S3c, S5b, and S6c exhibited significant binding affinity with multiple protein targets of the signaling cascade. Conclusion: Anticancer activities of compounds S3c, S5b, and S6c in cisplatin-resistant cell lines suggested that these ligands may contribute as lead compounds for the development of new anticancer drugs.

NOVEL TRF1 MODULATORS AND ANALOGUES THEREOF

Novel TRF1 modulators and analogues thereof. There is provided compounds of Formula I, wherein R, R1, R2 and X have meanings written in the description. Such compounds are useful as TRF1 inhibitors and, for that reason, as medicaments, in the treatment of cancer, particularly high cancer stem cell cancer like glioblastoma and lung cancer, and can be also useful for the development of additional TRF1 inhibitors and increasing knowledge about TRF1 activity.

AMINO ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES

The present disclosure provides certain amino acid derivatives that inhibit NF-kB activation and are therefore useful for the treatment of inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

A Novel Class of 7-Membered Heterocyclic Compounds

The work presented herein describes the synthesis of a formerly inaccessible class of heterocyclic compounds. The reaction relies on α-phthalimido-amides, which are readily prepared from amino acids in 2 simple reactions steps. Under amide activation conditions in which classical keteniminium ions are not formed, the nitrile solvent is incorporated into the new fused 7-membered ring system. Due to the absence of a keteniminium intermediate, the stereogenic information in the α-position is fully retained.

Kinetic investigation of the cyclopropanation process of fullerene C60 by halogenmethyl ketones under the conditions of the Bingel reaction

The kinetics of the Bingel reaction with halogenmethyl ketones and C60 fullerene has been studied in streaming mode by sampling the reaction mixture at different time intervals and separating the components using HPLC. A quantum-chemical simulation of this cyclopropanation process has been carried out with the DFT method. The activation parameters of the cycloaddition process were determined theoretically and experimentally and correlated with each other. It has been revealed that the use of chloromethyl ketone as the cyclopropanation agent is preferable to its brominated analogue, and a two-fold excess of the substrate with respect to fullerene is the best option for the selective synthesis of mono-adducts.

Flupirtine and retigabine as templates for ligand-based drug design of KV7.2/3 activators

Drug induced liver injury (DILI) and tissue discoloration led to the recent discontinuation of the therapeutic use of the closely related drugs flupirtine and retigabine, respectively. Experience gained with these drugs strongly suggests that heterotetramer, voltage-gated potassium channels 2 and 3 (KV7.2/3) are valid targets for effective treatment of pain and epilepsy. Because the adverse effects are not related to the mechanism of action, it appears promising to investigate chemical modifications of these clinically validated, drug-like leads. In the present retro-metabolic drug design study, a series of 43 compounds were synthesized and characterized with regard to KV7.2/3 opening activity and efficacy. The most active compound 22d displays excellent potency (EC50 = 4 nM) and efficacy (154%) as a KV7.2/3 opener. Limited aqueous solubility hampered toxicity testing at concentrations higher than 63 μM, but this concentration was nontoxic to two hepatocellular cell lines (HEP-G2 and TAMH) in culture. The slightly less active but more soluble compound 25b (EC50 = 11 nM, efficacy 111%) showed an improved toxicity/activity ratio compared to flupirtine by three orders of magnitude and represents an attractive lead structure for the development of safer analgesics and antiepileptics.

Oximino naphthoquinone compound and preparation and application methods thereof

The invention belongs to the technical field of medicinal compounds and medicines and relates to an oximino naphthoquinone compound and preparation and application methods thereof, particularly to a compound shown as formula (I). The oximino naphthoquinone compound can serve as a double-target selective inhibitor of STAT3 (signal transducer and activator of transcription-3) and IDO1 (indoleamine 2, 3-dioxygenase 1) for treating ovarian cancer, colon cancer, lung cancer and the like.

Chiral sensors for determining the absolute configurations of α-amino acid derivatives

A simple strategy for configurational assignments of alpha-amino acids has been developed by comparison of the proton NMR chemical shift values of the alpha hydrogens of N-phthaloyl protected alpha-amino acids in the presence of (R)-CSA 1 and (S)-CSA 1, respectively. Highly resolved NMR spectra can be obtained directly on the mixed solution of the chiral solvating agents with N-phthaloyl protected alpha-amino acids in NMR tubes, giving well distinguishable proton signals without interference which dramatically improve the accuracy of assignment and hasten the assigning procedure. The strategy is widely applicable for varied natural and non-natural amino acids.

Directing Group Participated Benzylic C(sp3)-H/C(sp2)-H Cross-Dehydrogenative Coupling (CDC): Synthesis of Azapolycycles

An efficient method to construct azapolycycles via directing group participated benzylic C(sp3)-H/C(sp2)-H cross-dehydrogenative coupling reactions is described. The reaction proceeded through a palladium catalyzed C(sp3)-H activation followed by coupling with a C(sp2)-H bond of quinoline to afford the azapolycyclic compounds. The reaction works with a broad substrate scope affording the products in moderate to good yields with excellent diastereoselectivities. Control experiments further supported the proposed mechanism.

Synthesis and study of modified polyvinyl alcohol containing amino acid moieties as anticancer agent

A series of new phthalimides compounds[3-7]a-i were synthesized from reaction of Malic anhydride, phthalic anhydride, nitro phthalic anhydride, 2-phenyl-4H-benzo[d][1,3]oxazin-4-one, 2-(4-nitrophenyl)-4H-benzo[d][1,3]oxazin-4-one with different amino acids as glycine, alanine, valine, leucine, isoleucine, serine, threonine, tyrosine and Phenyl alanine [1]a-i under fusion conditions. Compounds [3-7]a-i react with SOCl2 in the presence of benzene to produce compounds [8-12]a-i. Chemical modification of Poly(vinyl alcohol)were obtained by reaction of PVA with compounds [8-12]a-i using the dimethyl formamide to give compounds [13-17]a-i. The structure of the synthesized compounds was characterized by their analytical and spectral data as, IR spectra, 1H, 13C-NMR, Elemental analysis (CHN), UV-Vis Spectroscopy, Scanning electron microscopy (SEM), Antibacterial activity were screened via two kinds of bacteria. Also, anticancer activity were examined for most of the modified polyvinyl alcohol.